156 related articles for article (PubMed ID: 29517956)
1. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Anderson K; Ismaila N; Kyle RA
J Oncol Pract; 2018 Apr; 14(4):266-269. PubMed ID: 29517956
[No Abstract] [Full Text] [Related]
2. Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Terpos E; Dimopoulos MA
Lancet Oncol; 2010 Oct; 11(10):913-4. PubMed ID: 20863760
[No Abstract] [Full Text] [Related]
3. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
4. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.
Engelhardt M; Herget GW; Graziani G; Ihorst G; Reinhardt H; Ajayi S; Knop S; Wasch R
Haematologica; 2018 May; 103(5):755-758. PubMed ID: 29712821
[No Abstract] [Full Text] [Related]
5. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
6. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
7. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
8. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for bone lesions in multiple myeloma - what is its value?
Goldstein DA
Haematologica; 2018 May; 103(5):753-754. PubMed ID: 29712820
[No Abstract] [Full Text] [Related]
10. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
11. [Management of bone lesions in multiple myeloma].
Hata H; Mitsuya H
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma.
Zhou J; Sweiss K; Han J; Ko NY; Patel PR; Chiu BC; Calip GS
JAMA Netw Open; 2021 Jul; 4(7):e2118410. PubMed ID: 34313746
[TBL] [Abstract][Full Text] [Related]
13. [Prevention and treatment of multiple myeloma bone disease].
Ma J
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):292-4. PubMed ID: 23668196
[No Abstract] [Full Text] [Related]
14. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
15. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
[No Abstract] [Full Text] [Related]
16. The role of bisphosphonates in multiple myeloma.
Levy J; Roodman GD
Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
[TBL] [Abstract][Full Text] [Related]
17. Advances in the biology and treatment of bone disease in multiple myeloma.
Raje N; Roodman GD
Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
[TBL] [Abstract][Full Text] [Related]
18. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
19. Myeloma bone disease.
Berenson JR
Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
